VYNE Therapeutics to Participate in the 2nd Annual JAK Inhibitors Drug Development Digital Event

Rhea-AI Summary

VYNE Therapeutics announced that Dr. Iain Stuart will moderate a scientific panel discussion at the 2nd Annual JAK Inhibitors Drug Development Digital Event, occurring from June 29 to July 1, 2021. The discussion, set for June 30 at 2:40 PM Eastern Time, will focus on combinational opportunities with JAK inhibitors and ongoing research trends in immunology. The event aims to address the lack of JAK inhibitors in specific disease profiles and explore the potential benefits of combination therapeutic approaches.

BRIDGEWATER, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that Dr. Iain Stuart, Chief Scientific Officer, will participate in and moderate a scientific panel discussion at the 2^nd Annual JAK Inhibitors Drug Development Digital Event, to take place virtually June 29-July 1, 2021.

Event Details:

Day:	Wednesday, June 30, 2021
Time:	2:40pm Eastern Time
Panel:	Past, Present & Future Combinational Opportunities with JAKi

Topics to be addressed on the panel include the current dearth of JAK inhibitors in certain disease profiles and speculation on the use of combinational approaches and the benefits of combinational approaches for targeted therapeutic treatments. Discussion will also focus on current and future research trends in immunology to highlight particular opportunities for JAK inhibitors.

For more information on the JAK Inhibitor Drug Development Summit refer to https://jak-drugdevelopment.com/

About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.

With expertise in topical medicine innovation as a springboard, VYNE is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for AMZEEQ® (minocycline) topical foam, 4%, the world’s first topical minocycline, and for ZILXI® (minocycline) topical foam, 1.5%, the first minocycline product of any kind to be approved by the FDA for use in rosacea. For more information about our approved products, please see AMZEEQ’s Full Prescribing Information at AMZEEQ.com and ZILXI’s Full Prescribing Information at ZILXI.com.

For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

CONTACT:
Joyce Allaire
LifeSci Advisors, LLC
646-889-1200
jallaire@lifesciadvisors.com 

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com

FAQ

What is the purpose of VYNE's participation in the JAK Inhibitors Drug Development Event?

VYNE's participation intends to discuss combinational opportunities with JAK inhibitors and current research trends in immunology.

When is the JAK Inhibitors Drug Development Event taking place?

The event is scheduled for June 29 to July 1, 2021.

What time will Dr. Iain Stuart's panel discussion occur during the event?

Dr. Iain Stuart's panel discussion will take place on June 30, 2021, at 2:40 PM Eastern Time.

What key topics will be discussed in the JAK Inhibitors panel?

The panel will discuss the current lack of JAK inhibitors in certain diseases and the benefits of combinational therapeutic approaches.

What is VYNE Therapeutics known for?

VYNE Therapeutics is known for developing innovative therapies in dermatology, including FDA-approved products like AMZEEQ and ZILXI.